tiprankstipranks
Advertisement
Advertisement

HUMA Stock Latest News

Humacyte Earnings Call: Clinical Wins vs Cash Burn
Company AnnouncementsHumacyte Earnings Call: Clinical Wins vs Cash Burn
9d ago
HUMA
Humacyte confirms plans for ATEV supplemental biologic license application
PremiumThe Fly
Humacyte confirms plans for ATEV supplemental biologic license application
10d ago
HUMA
Humacyte Earns Buy Rating as Phase 3 V007 Data Publication Strengthens Regulatory and Commercial Outlook
PremiumRatings
Humacyte Earns Buy Rating as Phase 3 V007 Data Publication Strengthens Regulatory and Commercial Outlook
14d ago
HUMA
Humacyte publishes V007 results in The Lancet Digital Health
PremiumThe Fly
Humacyte publishes V007 results in The Lancet Digital Health
15d ago
HUMA
Humacyte reports Q2 EPS (16c), consensus (10c)
PremiumThe Fly
Humacyte reports Q2 EPS (16c), consensus (10c)
17d ago
HUMA
Humacyte price target lowered to $1 from $2 at Benchmark
PremiumThe FlyHumacyte price target lowered to $1 from $2 at Benchmark
17d ago
HUMA
Humacyte Faces Nasdaq Non-Compliance Warning as Share Price Risks Delisting and Future Capital Constraints
Premium
Company Announcements
Humacyte Faces Nasdaq Non-Compliance Warning as Share Price Risks Delisting and Future Capital Constraints
20d ago
HUMA
Humacyte’s Symvess Trauma Study: Real-World Data Push With Investor Upside
Premium
Company Announcements
Humacyte’s Symvess Trauma Study: Real-World Data Push With Investor Upside
20d ago
HUMA
Analyst Reiterates Buy on Humacyte, Maintains $4 Price Target Amid Dialysis Growth and Regulatory Catalysts
PremiumRatings
Analyst Reiterates Buy on Humacyte, Maintains $4 Price Target Amid Dialysis Growth and Regulatory Catalysts
21d ago
HUMA
HUMA Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
HUMA Upcoming Earnings Report: What to Expect?
24d ago
HUMA
Humacyte Receives Nasdaq Notice on Bid Price Noncompliance
PremiumCompany Announcements
Humacyte Receives Nasdaq Notice on Bid Price Noncompliance
1M ago
8K
HUMA
Buy Rating Reaffirmed on Humacyte as FDA Clears First-in-Human CABG Study; $2 Price Target Maintained
PremiumRatings
Buy Rating Reaffirmed on Humacyte as FDA Clears First-in-Human CABG Study; $2 Price Target Maintained
1M ago
HUMA
Humacyte announces FDA acceptance of CTEV IND application
PremiumThe FlyHumacyte announces FDA acceptance of CTEV IND application
1M ago
HUMA
Humacyte price target lowered to $1.25 from $1.50 at TD Cowen
Premium
The Fly
Humacyte price target lowered to $1.25 from $1.50 at TD Cowen
3M ago
HUMA
Humacyte Announces Underwritten Public Equity Offering to Fund Growth
Premium
Company Announcements
Humacyte Announces Underwritten Public Equity Offering to Fund Growth
3M ago
8K
HUMA
Humacyte price target raised to $4 from $3 at H.C. Wainwright
PremiumThe Fly
Humacyte price target raised to $4 from $3 at H.C. Wainwright
3M ago
HUMA
Humacyte 47.62M share Spot Secondary priced at $1.05
PremiumThe Fly
Humacyte 47.62M share Spot Secondary priced at $1.05
3M ago
HUMA
Humacyte TBA Spot Secondary; price range $1.05-$1.15
PremiumThe Fly
Humacyte TBA Spot Secondary; price range $1.05-$1.15
3M ago
HUMA
Humacyte Announces Positive Phase 3 Dialysis Access Results
PremiumCompany Announcements
Humacyte Announces Positive Phase 3 Dialysis Access Results
3M ago
8K
HUMA
Humacyte announces V012 study of ATEV meets primary endpoint
PremiumThe FlyHumacyte announces V012 study of ATEV meets primary endpoint
3M ago
HUMA
Humacyte announces common stock offering, no amount given
Premium
The Fly
Humacyte announces common stock offering, no amount given
3M ago
HUMA
Humacyte Shareholders Approve Governance Changes and Share Increase
Premium
Company Announcements
Humacyte Shareholders Approve Governance Changes and Share Increase
3M ago
8K
HUMA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >